Bone Biologics Corp: Executive Compensation Details Revealed
Ticker: BBLGW · Form: DEF 14A · Filed: Apr 23, 2025 · CIK: 1419554
| Field | Detail |
|---|---|
| Company | Bone Biologics Corp (BBLGW) |
| Form Type | DEF 14A |
| Filed Date | Apr 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, governance, stock-awards
Related Tickers: BBLG
TL;DR
Bone Biologics DEF 14A out: Exec comp details for 2024, stock/option awards disclosed.
AI Summary
Bone Biologics Corp filed a DEF 14A on April 23, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on stock awards, option awards, and their fair values for both PEO and Non-PEO members. Specific dollar amounts and vesting dates for these awards are provided within the filing.
Why It Matters
This filing provides transparency into how Bone Biologics Corp compensates its top executives, offering insights into the company's financial priorities and potential alignment of management interests with shareholder value.
Risk Assessment
Risk Level: medium — DEF 14A filings primarily concern executive compensation and corporate governance, which can indirectly impact stock performance but do not typically involve direct financial risks like debt or acquisitions.
Key Players & Entities
- Bone Biologics Corp (company) — Filer of the DEF 14A
- 2024-12-31 (date) — Fiscal year end for compensation details
- 20250423 (date) — Filing date of the DEF 14A
FAQ
What is the total compensation for the CEO in 2024?
The provided text does not contain specific dollar amounts for individual executive compensation, only references to aggregate values for stock and option awards.
When were the stock and option awards granted and vested?
The filing references 'VestingDateFairValueOfAwardsGrantedAndVestedDuringTheCoveredFiscalYearMember' for PEO and Non-PEO members, indicating these details are present but not quantified in the provided excerpt.
What is the fiscal year end for the reported compensation?
The fiscal year end for the reported compensation is December 31, 2024.
What is the filing type and date?
The filing type is DEF 14A, filed on April 23, 2025.
What industry does Bone Biologics Corp operate in?
Bone Biologics Corp operates in the ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES industry, SIC code 3842.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 23, 2025 regarding Bone Biologics Corp (BBLGW).